William Blair analyst Tim Lugo views Lundbeck's (HLUYY) acquisition of Alder Biopharmaceuticals (ALDR) as indicative of continued interest in the calcitonin gene-related peptide space from strategic buyers given the IV dosing and what is an increasingly competitive space for biologics. Following the deal, the analyst reiterates an Outperform rating on Biohaven Pharmaceutical (BHVN). The analyst sees an "active" Q4 for the company, which is expected to include the readout of the Phase III trial of rimegepant for the prevention of episodic migraine, top-line results from a Phase II/III trial of intranasal CGRP therapy BHV-3500, and completion of enrollment in Phase II/III trials of troriluzole for the treatment of obsessive-compulsive disorder, generalized anxiety disorder, and Alzheimer's disease.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here